Chief Executive Officer, Pathios Therapeutics

Stuart Hughes

Role	Organisation	Sources
Chief Executive Officer	Pathios Therapeutics	biomelbourne.org, Brandon BioCatalyst portfolio

Coverage

Stories naming Stuart Hughes. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.

Series B $25m

Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic

Cancer immunotherapy biotech Pathios Therapeutics has completed the initial tranche of a Series B round, bringing in Bristol Myers Squibb as a new strategic backer alongside prior backers Canaan and Brandon Capital.

biomelbourne.org 1 May 2024 Pathios Therapeutics Brandon Capital Bristol-Myers Squibb Canaan Stuart Hughes Dr Tom McCarthy

News

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022

UK cancer biotech Pathios Therapeutics, backed by Canaan Partners and Brandon Capital, presented preclinical data at a US conference showing its GPR65 inhibitor PTT-3213 shrank tumors in mouse models.

Brandon BioCatalyst portfolio 12 Apr 2022 Brandon Capital Canaan Partners Pathios Therapeutics Vida Strategic Partners Stuart Hughes Tim Brons

Something wrong? Tell us

Stuart Hughes

Roles

Coverage

Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic

Pathios Therapeutics Highlights Role of GPR65 as Critical Innate Immune Checkpoint in the Human Tumor Microenvironment and Reports Anti-Tumor Activity of GPR65 Inhibition During Podium Presentation at AACR 2022